第113届美国癌症研究协会（AACR）年会在2022年4月08~13召开了，该年会是世界上规模最大最重要的癌症研究会议，今年的会议主题是“解码癌症复杂性，整合科学改变患者结果”。本期内容【肿瘤资讯】为您整理了血液肿瘤每日研究汇总——白血病篇！后续几日小编将持续跟进相关内容！
研究进展
1.ceralasertib(Cerala)单药治疗或与acalabrutinib(Acala)联合治疗高危复发性/难治性(R/R)慢性淋巴细胞白血病(CLL)的1/2期结果
题目：Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
时间：April 8, 2022, 12:00 PM - 1:00 PM
会议类型：Session OPO.CT02.01 - Phase II Clinical Trials
演讲者：Wojciech Jurczak
摘要号：CT532
2. InO-VATEⅢ期试验：伊珠单抗奥唑米星(InO)治疗的复发性/难治性急性淋巴细胞白血病(ALL)患者的白血病分子特征与疗效
题目：Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial
时间：April 10, 2022, 4:35 PM - 4:45 PM
会议类型：Session CTMS01 - Biomarker Advances in Clinical Trials
演讲者：Yaqi Zhao
摘要号：CT027
3. CAPTIVATEⅡ试验：固定持续时间(FD)伊布替尼(Ibr)+ 维奈托克(Ven)一线治疗具有高风险特征的慢性淋巴细胞白血病(CLL)患者
题目：Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL) in patients (pts) with high-risk features: phase 2 CAPTIVATE study
时间: April 11, 2022, 2:35 PM - 2:45 PM
会议类型：Session CTMS02 - Patient Selection Strategies for Molecularly
演讲者：John N. Allan,
摘要号：CT028
4.BRUIN Ⅰb期研究：Pirtobrutinib与venetoclax±利妥昔单抗联合治疗复发性/难治性慢性淋巴细胞白血病疗效揭晓
题目：Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study
时间：April 11, 2022, 1:30 PM - 5:00 PM
会议类型：Session PO.CT01.01 - Phase I Clinical Trials 1
演讲者： Lindsey E. Roeker
摘要号：CT138 / 5
5. 同种异体TruUCAR™GC502治疗复发性/难治性B细胞急性淋巴细胞白血病(r/r B-ALL)患者中安全性和疗效
题目：Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
时间：April 12, 2022, 9:00 AM - 12:30 PM
会议类型：Session PO.CT01.02 - Phase I Clinical Trials 2
演讲者：Xinxin Wang
摘要号：CT196 / 21
6. 新型口服不可逆menin抑制剂BMF-219单药治疗复发性/难治性(R/R)急性白血病(AL)、弥漫性大B细胞淋巴瘤(DLBCL)和多发性骨髓瘤(MM)患者
题目：A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as single-agent in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM)
时间April 12, 2022, 9:00 AM - 12:30 PM
会议类型：Session PO.CT01.03 - Phase I Trials in Progress 1
演讲者：Farhad Ravandi-Kashani
摘要号：CT210 / 10
LBA
1. 整合多组学分析确定表观遗传调控因子PRC2是对抗白血病免疫逃逸和复发的治疗靶点
题目：Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse
会议类型：Session OPO.IM01.01 - Tumor Immunobiology
演讲者：Valentina Gambacorta
摘要号：LB563
2. 扩增的EPOR/JAK2基因新定义了急性红系白血病的独特亚型
题目：Amplified EPOR/JAK2 genes definea unique subtype of acute erythroid leukemia
会议类型：Session OPO.CL11.01 - Biomarkers
演讲者：June Takeda
摘要号：LB518
3. 表达CCR7的T细胞急性淋巴细胞白血病小鼠模型为开发预防CNS侵袭的新型抗CCR7疗法提供了新平台
题目：CCR7-expressing T-cell acute lymphoblastic leukemia mouse model provides a platform for developing novel anti-CCR7 therapies to prevent CNS invasion.
时间：April 10, 2022, 1:30 PM - 5:00 PM
会议类型：Session LBPO.TB01 - Late-Breaking Research: Tumor Biology 1
演讲者：Angel Torres,
摘要号：LB015 / 3
4. 靶向微环境中的细胞作为慢性淋巴细胞白血病的新型治疗策略
题目：Targeting cells in the microenvironment as a novel therapeutic strategy for chronic lymphocytic leukemia
Presenter/Authors
时间April 11, 2022, 9:00 AM - 12:30 PM
会议类型：Session LBPO.TB02 - Late-Breaking Research: Tumor Biology 2
演讲者：Giovanna Merchand Reyes
摘要号：LB050 / 2
5. 现成脐带血FLT3 CAR-NK细胞免疫治疗急性髓性白血病
题目：Off-the-shelf cord blood FLT3 CAR-NK cells for immunotherapy of acute myeloid leukemia.
时间April 11, 2022, 1:30 PM - 5:00 PM
会议类型：Session LBPO.IM01 - Late-Breaking Research: Immunology 1
演讲者：Anthony G. Mansou
摘要号LB102 / 9
6. 新型CAR-T：基于DNA的T细胞活化来产生具有增强抗白血病细胞毒性
题目：Novel DNA-based-T-cell-activation for the generation of chimeric antigen receptor T cells with enhanced anti-leukemia cytotoxicity
时间:April 11, 2022, 1:30 PM - 5:00 PM
会议类型：Session LBPO.IM01 - Late-Breaking Research: Immunology
演讲者：Mehdi Benzaoui
摘要号LB103 / 10
1.Wojciech Jurczak, Nagah Elmusharaf, Christopher P,et al. Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 2022 AACR abs CT532.
2. Yaqi Zhao, A Douglas Laird, Kathryn Roberts, et al. Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.2022 AACR abs CT027.
3. John N. Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia, et al. Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL) in patients (pts) with high-risk features: phase 2 CAPTIVATE study.2022 AACR abs CT028.
4. Lindsey E. Roeker, Anthony R. Mato, Jennifer R. Brown, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study.2022 AACR abs CT138 / 5.
5. Shiqi Li, Xinxin Wang, Zhongtao Yuan, Lin Liu ，et al. Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). 2022 AACR abs CT196 / 21.
6. Farhad Ravandi-Kashani, Ashwin Kishtagari, Hetty Carraway, et al. A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as single-agent in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). 2022 AACR abs CT210 / 10.
7.Valentina Gambacorta, Stefano Beretta, Martina Ciccimarra, et al. Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse.2022 AACR abs 563
8.. June Takeda, Kenichi Yoshida, Masahiro M, et al. Amplified EPOR/JAK2 genes definea unique subtype of acute erythroid leukemia.2022 AACR abs LB518
9. Angel Torres, Aaron Vazquez, Sean Glenn, et al. CCR7-expressing T-cell acute lymphoblastic leukemia mouse model provides a platform for developing novel anti-CCR7 therapies to prevent CNS invasion.2022 AACR abs LB015 / 3 .
10. Giovanna Merchand Reyes, Ramasamy Santhanam, Frank H. Robledo Avila, et al. Targeting cells in the microenvironment as a novel therapeutic strategy for chronic lymphocytic leukemia.2022 AACR abs LB050 / 2.
11. Mehdi Benzaoui, Sooraj R. Achar, Vandana Keskar, et al. Novel DNA-based-T-cell-activation for the generation of chimeric antigen receptor T cells with enhanced anti-leukemia cytotoxicity.2022 AACR abs LB103 / 10.
12. Catherine Pham-Danis, Lillie Leach, Christopher Ebmeier, et al. A novel adjunctive LAT-activating CAR T (ALA-CART) cell platform demonstrates enhanced antigen sensitivity and eradication of antigen-low leukemia. 2022 AACR abs 3607.
排版编辑：肿瘤资讯-luna
苏公网安备32059002004080号
